LFCR LIFECORE BIOMEDICAL INC revenue, earnings and financials
For the quarter ended June 30, 2026, LIFECORE BIOMEDICAL INC reported revenue of $34.2M, net income of −$6.16M and diluted EPS of −$0.19; for the fiscal year ended May 2025 revenue was $129M, up 0.5% on the year before.
LFCR annual revenue and earnings
- Fiscal year ended May 2025: revenue $129M, gross profit $40.3M, operating income −$17.2M, net income −$38.7M (margin -30.0%), EPS −$1.27
- Fiscal year ended May 2024: revenue $128M, gross profit $41.9M, operating income −$8.84M, net income $12.0M (margin 9.4%), EPS $0.33
- Fiscal year ended May 2023: revenue $103M, gross profit $28.0M, operating income −$21.8M, net income −$99.6M (margin -96.4%), EPS −$3.32
- Fiscal year ended May 2022: revenue $111M, gross profit $39.1M, operating income −$11.8M, net income −$117M (margin -104.9%), EPS −$3.97
LFCR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $34.2M, net income −$6.16M, EPS −$0.19
- Quarter ended Mar 31, 2026: revenue $23.2M, net income −$15.0M, EPS −$0.43
- Quarter ended Sep 30, 2025: revenue $31.1M, net income −$9.99M, EPS −$0.29
- Quarter ended May 25, 2025: revenue $36.4M (down 3.8% year over year), net income −$1.15M, EPS −$0.06
- Quarter ended Feb 23, 2025: revenue $35.2M (down 1.5% year over year), net income −$14.8M, EPS −$0.42
- Quarter ended Nov 24, 2024: revenue $32.6M (up 8.0% year over year), net income −$6.57M, EPS −$0.25
- Quarter ended Aug 25, 2024: revenue $24.7M (up 0.7% year over year), net income −$16.2M, EPS −$0.53
- Quarter ended May 26, 2024 (from the annual report): revenue $37.9M (up 21.6% year over year), net income −$7.10M, EPS −$0.13
- Quarter ended Feb 25, 2024: revenue $35.7M (up 34.5% year over year), net income $15.6M, EPS $0.42
- Quarter ended Nov 26, 2023: revenue $30.2M (up 37.9% year over year), net income $14.2M, EPS $0.39
- Quarter ended Aug 27, 2023: revenue $24.5M (up 3.4% year over year), net income −$10.8M, EPS −$0.35
- Quarter ended May 28, 2023 (from the annual report): revenue $31.1M (up 10.8% year over year), net income −$39.3M, EPS −$1.32
- Quarter ended Feb 26, 2023: revenue $26.5M (down 24.7% year over year), net income −$36.5M, EPS −$1.20
- Quarter ended Nov 27, 2022: revenue $21.9M (down 14.6% year over year), net income −$12.8M, EPS −$0.43
- Quarter ended Aug 28, 2022: revenue $23.7M (up 6.2% year over year), net income −$11.0M, EPS −$0.37
- Quarter ended May 29, 2022 (from the annual report): revenue $28.1M (down 37.4% year over year), net income −$55.3M, EPS −$1.88
- Quarter ended Feb 27, 2022: revenue $35.2M (up 26.7% year over year), net income −$13.6M, EPS −$0.46
- Quarter ended Nov 28, 2021: revenue $25.6M, net income −$38.5M, EPS −$1.31
- Quarter ended Aug 29, 2021: revenue $22.3M, net income −$9.39M, EPS −$0.32
- Quarter ended May 30, 2021: revenue $44.9M, net income n/a, EPS n/a
LFCR cash flow, buybacks and dividends
- Fiscal year ended May 2025: operating cash flow −$206K, share buybacks n/a
- Fiscal year ended May 2024: operating cash flow $257K, share buybacks n/a
- Fiscal year ended May 2023: operating cash flow −$17.4M, share buybacks n/a
- Fiscal year ended May 2022: operating cash flow −$22.6M, share buybacks n/a
LFCR balance sheet
- Jun 30, 2026: cash $17.2M, total assets $230M, total liabilities $213M, shareholders' equity −$34.1M
- Mar 31, 2026: cash $20.8M, total assets $225M, total liabilities $205M, shareholders' equity −$28.4M
- Dec 31, 2025: cash $17.5M, total assets $232M, total liabilities $198M, shareholders' equity −$14.2M
- Sep 30, 2025: cash $18.9M, total assets $235M, total liabilities $198M, shareholders' equity −$10.5M
- May 25, 2025: cash $8.27M, total assets $239M, total liabilities $192M, shareholders' equity −$861K
- Feb 23, 2025: cash $5.42M, total assets $238M, total liabilities $190M, shareholders' equity $2.22M
- Nov 24, 2024: cash $9.46M, total assets $255M, total liabilities $196M, shareholders' equity $15.4M, long-term debt $111M
- Aug 25, 2024: cash n/a, total assets $247M, total liabilities $207M, shareholders' equity −$3.94M, long-term debt $106M
What is LFCR's revenue?
LIFECORE BIOMEDICAL INC reported $129M of revenue for the fiscal year ended May 2025.
Is LFCR profitable?
No. LIFECORE BIOMEDICAL INC lost $38.7M in its latest fiscal year.